Bartolome Celli1, Kay Tetzlaff2,3, Gerard Criner4, Michael I Polkey5, Frank Sciurba6, Richard Casaburi7, Ruth Tal-Singer8, Ariane Kawata9, Debora Merrill10, Stephen Rennard11. 1. 1 Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 2. 2 Boehringer Ingelheim, Ingelheim, Germany. 3. 3 Department of Sports Medicine, University of Tuebingen, Tuebingen, Germany. 4. 4 Temple University Medical Center, Philadelphia, Pennsylvania. 5. 5 National Institute for Health Research Respiratory Biomedical Research Unit at the Royal Brompton and Harefield National Health Service Foundation Trust and Imperial College, London, United Kingdom. 6. 6 University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 7. 7 Rehabilitation Clinical Trials Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California. 8. 8 GlaxoSmithKline Research and Development, King of Prussia, Pennsylvania. 9. 9 Evidera, Bethesda, Maryland. 10. 10 COPD Foundation, Washington, District of Columbia; and. 11. 11 Division of Pulmonary, Allergy, Sleep and Critical Care Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Abstract
RATIONALE: The 6-minute-walk distance (6MWD) test predicts mortality in chronic obstructive pulmonary disease (COPD). Whether variability in study type (observational vs. interventional) or region performed limits use of the test as a stratification tool or outcome measure for therapeutic trials is unclear. OBJECTIVES: To analyze the original data from several large observational studies and from randomized clinical trials with bronchodilators to support the qualification of the 6MWD test as a drug development tool in COPD. METHODS: Original data from 14,497 patients with COPD from six observational (n = 9,641) and five interventional (n = 4,856) studies larger than 100 patients and longer than 6 months in duration were included. The geographical, anthropometrics, FEV1, dyspnea, comorbidities, and health status scores were measured. Associations between 6MWD and mortality, hospitalizations, and exacerbations adjusted by study type, age, and sex were evaluated. Thresholds for outcome prediction were calculated using receiver operating curves. The change in 6MWD after inhaled bronchodilator treatment and surgical lung volume reduction were analyzed to evaluate the responsiveness of the test as an outcome measure. MEASUREMENTS AND MAIN RESULTS: The 6MWD was significantly lower in nonsurvivors, those hospitalized, or who exacerbated compared with those without events at 6, 12, and greater than 12 months. At these time points, the 6MWD receiver operating characteristic curve-area under the curve to predict mortality was 0.71, 0.70, and 0.68 and for hospitalizations was 0.61, 0.60, and 0.59, respectively. After treatment, the 6MWD was not different between placebo and bronchodilators but increased after surgical lung volume reduction compared with medical therapy. Variation across study types (observational or therapeutic) or regions did not confound the ability of 6MWD to predict outcome. CONCLUSIONS: The 6MWD test can be used to stratify patients with COPD for clinical trials and interventions aimed at modifying exacerbations, hospitalizations, or death.
RATIONALE: The 6-minute-walk distance (6MWD) test predicts mortality in chronic obstructive pulmonary disease (COPD). Whether variability in study type (observational vs. interventional) or region performed limits use of the test as a stratification tool or outcome measure for therapeutic trials is unclear. OBJECTIVES: To analyze the original data from several large observational studies and from randomized clinical trials with bronchodilators to support the qualification of the 6MWD test as a drug development tool in COPD. METHODS: Original data from 14,497 patients with COPD from six observational (n = 9,641) and five interventional (n = 4,856) studies larger than 100 patients and longer than 6 months in duration were included. The geographical, anthropometrics, FEV1, dyspnea, comorbidities, and health status scores were measured. Associations between 6MWD and mortality, hospitalizations, and exacerbations adjusted by study type, age, and sex were evaluated. Thresholds for outcome prediction were calculated using receiver operating curves. The change in 6MWD after inhaled bronchodilator treatment and surgical lung volume reduction were analyzed to evaluate the responsiveness of the test as an outcome measure. MEASUREMENTS AND MAIN RESULTS: The 6MWD was significantly lower in nonsurvivors, those hospitalized, or who exacerbated compared with those without events at 6, 12, and greater than 12 months. At these time points, the 6MWD receiver operating characteristic curve-area under the curve to predict mortality was 0.71, 0.70, and 0.68 and for hospitalizations was 0.61, 0.60, and 0.59, respectively. After treatment, the 6MWD was not different between placebo and bronchodilators but increased after surgical lung volume reduction compared with medical therapy. Variation across study types (observational or therapeutic) or regions did not confound the ability of 6MWD to predict outcome. CONCLUSIONS: The 6MWD test can be used to stratify patients with COPD for clinical trials and interventions aimed at modifying exacerbations, hospitalizations, or death.
Authors: Luis Puente-Maestu; Paolo Palange; Richard Casaburi; Pierantonio Laveneziana; François Maltais; J Alberto Neder; Denis E O'Donnell; Paolo Onorati; Janos Porszasz; Roberto Rabinovich; Harry B Rossiter; Sally Singh; Thierry Troosters; Susan Ward Journal: Eur Respir J Date: 2016-01-21 Impact factor: 16.671
Authors: Matthew Moll; Dandi Qiao; Elizabeth A Regan; Gary M Hunninghake; Barry J Make; Ruth Tal-Singer; Michael J McGeachie; Peter J Castaldi; Raul San Jose Estepar; George R Washko; James M Wells; David LaFon; Matthew Strand; Russell P Bowler; MeiLan K Han; Jorgen Vestbo; Bartolome Celli; Peter Calverley; James Crapo; Edwin K Silverman; Brian D Hobbs; Michael H Cho Journal: Chest Date: 2020-04-27 Impact factor: 9.410
Authors: William W Stringer; Janos Porszasz; Surya P Bhatt; Meredith C McCormack; Barry J Make; Richard Casaburi Journal: Chronic Obstr Pulm Dis Date: 2019-07-24
Authors: Michael I Polkey; Jens Praestgaard; Amy Berwick; Frits M E Franssen; Dave Singh; Michael C Steiner; Richard Casaburi; Hanns-Christian Tillmann; Estelle Lach-Trifilieff; Ronenn Roubenoff; Daniel S Rooks Journal: Am J Respir Crit Care Med Date: 2019-02-01 Impact factor: 21.405
Authors: Maggie Tabberer; Victoria S Benson; Heather Gelhorn; Hilary Wilson; Niklas Karlsson; Hana Müllerova; Shailendra Menjoge; Stephen I Rennard; Ruth Tal-Singer; Debora Merrill; Paul W Jones Journal: Chronic Obstr Pulm Dis Date: 2017-03-13
Authors: Stefanie Elizabeth Mason; Rafael Moreta-Martinez; Wassim W Labaki; Matthew Strand; David Baraghoshi; Elizabeth A Regan; Jessica Bon; Ruben San Jose Estepar; Richard Casaburi; Merry-Lynn N McDonald; Harry Rossiter; Barry J Make; Mark T Dransfield; MeiLan K Han; Kendra A Young; Greg Kinney; John E Hokanson; Raul San Jose Estepar; George R Washko Journal: Thorax Date: 2021-02-11 Impact factor: 9.139
Authors: Matthew Strand; Erin Austin; Matthew Moll; Katherine A Pratte; Elizabeth A Regan; Lystra P Hayden; Surya P Bhatt; Aladin M Boriek; Richard Casaburi; Edwin K Silverman; Spyridon Fortis; Ingo Ruczinski; Harald Koegler; Harry B Rossiter; Mariaelena Occhipinti; Nicola A Hanania; Hirut T Gebrekristos; David A Lynch; Ken M Kunisaki; Kendra A Young; Jessica C Sieren; Margaret Ragland; John E Hokanson; Sharon M Lutz; Barry J Make; Gregory L Kinney; Michael H Cho; Massimo Pistolesi; Dawn L DeMeo; Frank C Sciurba; Alejandro P Comellas; Alejandro A Diaz; Igor Barjaktarevic; Russell P Bowler; Richard E Kanner; Stephen P Peters; Victor E Ortega; Mark T Dransfield; James D Crapo Journal: Chronic Obstr Pulm Dis Date: 2020-10
Authors: Fang Liu; Raymond C C Tsang; Alice Y M Jones; Mingchao Zhou; Kaiwen Xue; Miaoling Chen; Yulong Wang Journal: PLoS One Date: 2021-05-25 Impact factor: 3.240
Authors: Chunrui Zou; Frank Li; Jiwoong Choi; Babak Haghighi; Sanghun Choi; Prathish K Rajaraman; Alejandro P Comellas; John D Newell; Chang Hyun Lee; R Graham Barr; Eugene Bleecker; Christopher B Cooper; David Couper; Meilan Han; Nadia N Hansel; Richard E Kanner; Ella A Kazerooni; Eric C Kleerup; Fernando J Martinez; Wanda O'Neal; Robert Paine; Stephen I Rennard; Benjamin M Smith; Prescott G Woodruff; Eirc A Hoffman; Ching-Long Lin Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-05-31